RecruitingPhase 2NCT06297226

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

Sponsor

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Enrollment

230 participants

Start Date

Mar 21, 2024

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests arlocabtagene autoleucel, a CAR T-cell therapy that uses your own genetically modified immune cells to target and kill multiple myeloma cells, for patients whose myeloma has come back or stopped responding after multiple treatments. **You may be eligible if...** - You have multiple myeloma that has returned or is no longer responding to treatment - You have received at least 4 different types of myeloma treatment, including an immunomodulatory drug, a proteasome inhibitor, an anti-CD38 antibody, and an anti-BCMA therapy, across at least 3 treatment lines - Your disease is measurable at the time of screening - You are generally well enough to participate (ECOG 0 or 1) **You may NOT be eligible if...** - Your myeloma has spread to the brain or spinal fluid - You have an active, serious infection - You have previously been treated with a therapy targeting GPRC5D - You have not completed the required washout period from your last myeloma treatment Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALArlocabtagene Autoleucel

Specified dose on specified days

Locations(52)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Banner MD Anderson Cancer Center

Gilbert, Arizona, United States

University of Arkansas for Medical Sciences

Little Rock, Arkansas, United States

UCLA Hematology/Oncology - Westwood (Building 200 Suite 214)

Los Angeles, California, United States

UCSF Helen Diller Medical Center at Parnassus Heights

San Francisco, California, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Mayo Clinic in Florida

Jacksonville, Florida, United States

Miami Cancer Institute at Baptist Health, Inc.

Miami, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Winship Cancer Institute of Emory University

Atlanta, Georgia, United States

Northside Hospital

Atlanta, Georgia, United States

Northwestern Memorial Hospital

Chicago, Illinois, United States

University of Chicago Medical Center

Chicago, Illinois, United States

University of Iowa

Iowa City, Iowa, United States

The University of Kansas Cancer Center - Westwood

Westwood, Kansas, United States

Norton Women's and Children's Hospital

Louisville, Kentucky, United States

Local Institution - 0065

Baltimore, Maryland, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Mayo Clinic in Rochester, Minnesota

Rochester, Minnesota, United States

Washington University School of Medicine

St Louis, Missouri, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Roswell Park Cancer Institute

Buffalo, New York, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

University of North Carolina Medical Center

Chapel Hill, North Carolina, United States

Local Institution - 0067

Charlotte, North Carolina, United States

Oncology Hematology Care

Cincinnati, Ohio, United States

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

Oregon Health and Science University

Portland, Oregon, United States

Local Institution - 0070

Philadelphia, Pennsylvania, United States

Tennessee Oncology

Nashville, Tennessee, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Local Institution - 0069

Austin, Texas, United States

UT Southwestern Medical Center

Dallas, Texas, United States

University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute

San Antonio, Texas, United States

LDS Hospital

Salt Lake City, Utah, United States

Virginia Oncology Associates

Norfolk, Virginia, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

University Hospital and UW Health Clinics

Madison, Wisconsin, United States

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia

Royal Brisbane and Women's Hospital

Brisbane, Queensland, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

St Vincent's Hospital

Melbourne, Victoria, Australia

Arthur J.E. Child Comprehensive Cancer Centre

Calgary, Alberta, Canada

McGill University Health Centre

Montreal, Quebec, Canada

Nagoya City University Hospital

Nagoya, Aichi-ken, Japan

Hyogo Medical University Hospital

Nishinomiya, Hyōgo, Japan

Chiba University Hospital

Chiba, Japan

University Hospital,Kyoto Prefectural University of Medicine

Kyoto, Japan

Japanese Red Cross Medical Center

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06297226

Related Trials

Tissue Collection for Studies of Lymph Cancer

NCT016768052 locations

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

NCT0617988874 locations

A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT0558361716 locations

18F-Fluciclovine PET/CT in Multiple Myeloma

NCT061038381 location

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT059471361 location